Pfizer/Pharmacia Merger: Tidbits From The SEC Filings
Executive Summary
COX-2 co-marketing amendment: Pfizer would gain majority control over Pfizer/Pharmacia COX-2 co-marketing executive committee should Pharmacia terminate the merger agreement under certain conditions, Pfizer's Aug. 14 S-4 merger filing with the Securities & Exchange Commission states. Pfizer would name three members to the five-person committee should Pharmacia end the deal; Pfizer is currently represented by two members. The company would also be able to appoint a chairperson to "any or all" of the six subcommittees of the executive committee under the amended agreement. The merger breakup fee is $1.6 bil...